Singapore markets close in 3 hours 32 minutes
Straits Times Index
3,266.02 +12.23 (+0.38%) Nikkei
29,187.54 +318.63 (+1.10%) Hang Seng
20,013.63 +183.11 (+0.92%) FTSE 100
7,536.06 +26.91 (+0.36%) BTC-USD
24,110.81 +229.02 (+0.96%) CMC Crypto 200
575.43 +3.51 (+0.61%)
PFE Jun 2023 45.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:16AM EDT. Market open.
| Previous close | 7.84 |
| Open | 7.84 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 45.00 |
| Expiry date | 2023-06-16 |
| Day's range | 7.84 - 7.84 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Zacks
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
- Yahoo Finance Video
UK approves COVID vaccine that targets Omicron subvariants
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
- Motley Fool
1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.
© 2022 Yahoo. All rights reserved.
